KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short-term Investments (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Short-term Investments for 16 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 27.25% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, down 27.25%, and an annual FY2025 reading of $1.3 billion, down 27.25% over the prior year.
  • Short-term Investments was $1.3 billion for Q4 2025 at Alnylam Pharmaceuticals, down from $1.6 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $1.7 billion in Q4 2024 and bottomed at $2.2 million in Q4 2022.
  • Average Short-term Investments over 5 years is $904.4 million, with a median of $1.3 billion recorded in 2021.
  • The sharpest move saw Short-term Investments crashed 99.86% in 2022, then soared 78220.58% in 2024.
  • Year by year, Short-term Investments stood at $1.5 billion in 2021, then plummeted by 99.86% to $2.2 million in 2022, then increased by 1.57% to $2.2 million in 2023, then skyrocketed by 78220.58% to $1.7 billion in 2024, then decreased by 27.25% to $1.3 billion in 2025.
  • Business Quant data shows Short-term Investments for ALNY at $1.3 billion in Q4 2025, $1.6 billion in Q1 2025, and $1.7 billion in Q4 2024.